RO7234292

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, Hoffmann-La Roche

Conditions

Huntingtons DiseaseProdromal and Early Manifest Huntington’s Disease

Phase 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Huntington’s Disease

Active, not recruitingCTIS2023-503928-10-00

F. Hoffmann-La Roche AGProdromal and Early Manifest Huntington’s Disease

Start: 2023-02-01Target: 162Updated: 2025-10-15

Phase 3

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

CompletedNCT03761849

Hoffmann-La RocheHuntingtons Disease

Start: 2019-01-23End: 2022-03-24Updated: 2024-03-01

Related Papers

Longitudinal assessment of chorea in Huntington’s disease using digital passive monitoring

npj Digital Medicine2026-04-24

Modeling Disease Progression and Placebo Response in Huntington Disease: Insights From Enroll-HD and GENERATION HD1 Cohorts.

2025-05-023 citations

A digital motor score for sensitive detection of progression in Huntington’s disease

Brain2025-04-111 citations

Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to pharmacy records.

2024-12-121 citations

Recent advances in RNA-targeting therapy for neurological diseases

Neural Regeneration Research2023-04-103 citations

An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons.

2022-11-1050 citations

E10 Cross-sectional exploration of the clinical utility of brain age as an imaging-based marker of disease pathology in Huntington’s disease (HD) based on the tominersen phase III trial generation HD 1

2022-09-012 citations

J03 Evaluating tominersen effect on self-reported quality of life (QoL) with high-frequency longitudinal, digital euroqol 5-dimensions 5-level (EQ-5D-5L) survey in generation HD1, a phase III trial of tominersen in adult individuals with manifest Huntington’s disease (HD)

2022-09-011 citations

J02 Quantitative analyses of pooled tominersen clinical data to support dose selection (rationale) for the new phase II study

2022-09-011 citations

J04 Benchmarking enroll-HD to a phase III placebo cohort from generation HD1 to inform clinical trial planning

2022-09-01

F14 Collaborating with the community to conduct clinical trials in huntington’s disease: lessons from the tominersen phase iii generation HD1 study

2021-09-012 citations